{"id":4508,"date":"2025-03-31T18:12:10","date_gmt":"2025-03-31T18:12:10","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/drotrecogin-alfa-txt\/"},"modified":"2025-03-31T18:12:10","modified_gmt":"2025-03-31T18:12:10","slug":"drotrecogin-alfa-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/drotrecogin-alfa-txt\/","title":{"rendered":"drotrecogin alfa.txt"},"content":{"rendered":"

drotrecogin alfa<\/h1>\n

CLINICAL USE <\/H3>
\nTreatment of adult patients with severe sepsis with multiple organ failure

DOSE IN NORMAL RENAL FUNCTION <\/H3>24 micrograms\/kg\/hour for 96 hours

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Approx 55 000<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : No data<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :8.2\u201331.2 litres<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :13 minutes\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unlikely to be dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Heparin: avoid concomitant use with high dose heparin\n
  • Thrombolytic therapy: avoid for 3 days before administering drotrecoginOral anticoagulants, antiplatelets: avoid for 7 days before administering drotrecogin

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Water for injection

    Route <\/H4>

    IV infusion <\/H4>

    Rate of Administration <\/H4>24 micrograms\/kg\/hour

    Comments<\/H4>Further dilute with sodium chloride 0.9% to a concentration of 100\u2013200 mcg\/mLMinimum volume: 20 mg in 50 mL. (UK Critical Care Group, Minimum Infusion Volumes for fluid restricted critically ill patients, 3rd Edition, 2006)

    OTHER INFORMATION <\/H4>No anticoagulation is required for haemofiltration as the drotrecogin acts as an anticoagulantCan be started 12 hours after major invasive procedures or surgeryClearance is reduced by 30% in renal impairment but no dose reduction is required Has a short half-life of 13 minutes and a \u03b2-half-life of 1.6 hours\n
  • Plasma clearance: Patients with sepsis: 41.8 L\/hour \u2014Healthy subjects: 28.1 L\/hour \u2014Haemodialysis patents: 30 L\/hour \u2014Peritoneal dialysis patients: 23 L\/hour
    \n","protected":false},"excerpt":{"rendered":"

    drotrecogin alfa CLINICAL USE Treatment of adult patients with severe<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4508","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4508"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4508\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}